Balar Discusses Current and Emerging Immunotherapy Treatments in Urothelial Carcinoma – Targeted Oncology
Targeted Oncology |
Balar Discusses Current and Emerging Immunotherapy Treatments in Urothelial Carcinoma
Targeted Oncology In the current era, where we have single-agent immunotherapy as approved agents and it is essentially the defacto second-line agent of choice, patients who are PD-L1–negative may also potentially benefit. The real challenge is deciding ultimately if a … |
